Pharmaceutical Brand Commercialization Committees Represent Nearly All Functions by Phase 3, Finds New Study by Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwired - August 26, 2015) - To be competitive in today's commercial landscape, pharmaceutical brands require support from stakeholders throughout the company. According to a new study by pharmaceutical intelligence firm Cutting Edge Information, life sciences organizations typically implement cross-functional brand commercialization committees to drive product development and maximize commercial success. These groups are often tasked with making key brand strategy decisions and with coordinating a broad range of brand activities throughout the product lifecycle.

The study, "Pharmaceutical Commercialization Profiles: Driving Brand Success with Better Budgeting and Timing," found that commercialization committees include representatives from new product planning teams at 80% of surveyed companies. Sixty-percent of surveyed companies have members from clinical development, legal and market research groups on these early-stage committees. Less than half of surveyed firms look to other internal functions during early brand development.

"As products mature, brand commercialization committees change as additional experts are called upon to drive brand decisions," said Victoria Cavicchi, research analyst at Cutting Edge Information. "As these committees grow in size, so too does the number of teams represented." By Phase 3, more than 50% of surveyed companies have representation from each function -- from new product planning to medical affairs to market access to sales -- on committees. All surveyed companies call on regulatory, pricing and reimbursement and marketing and commercial stakeholders.

"Pharmaceutical Commercialization Profiles: Driving Brand Success with Better Budgeting and Timing," available at http://www.cuttingedgeinfo.com/research/marketing/brand-commercialization-launch/, examines specific brand commercial spending throughout key parts of the product lifecycle. Report highlights include:

• An overview of resourcing medical affairs, market access and marketing and commercial expenditures from pre-clinical development to two years post-product launch
• Data on staffing brand commercialization committees and timing specific brand activities and assessments
• Profiles of more than 20 pharmaceutical brands for early brand development, late-stage brand development and post-launch support

For more information about pharmaceutical brand commercialization, please visit http://www.cuttingedgeinfo.com/research/marketing/brand-commercialization-launch/.